Cidara End Period Cash Flow from 2010 to 2025

CDTX Stock  USD 24.90  1.05  4.40%   
Cidara Therapeutics End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow is likely to outpace its year average in 2025. During the period from 2010 to 2025, Cidara Therapeutics End Period Cash Flow regression line of annual values had r-squared of  0.28 and arithmetic mean of  39,750,756. View All Fundamentals
 
End Period Cash Flow  
First Reported
2013-12-31
Previous Quarter
164.4 M
Current Value
127.4 M
Quarterly Volatility
30.8 M
 
Yuan Drop
 
Covid
Check Cidara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cidara Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 210.4 K, Selling General Administrative of 14 M or Other Operating Expenses of 63.2 M, as well as many indicators such as Price To Sales Ratio of 1.19, Dividend Yield of 0.0 or Days Sales Outstanding of 111. Cidara financial statements analysis is a perfect complement when working with Cidara Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cidara Therapeutics Correlation against competitors.
For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.

Latest Cidara Therapeutics' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Cidara Therapeutics over the last few years. It is Cidara Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cidara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Cidara End Period Cash Flow Regression Statistics

Arithmetic Mean39,750,756
Geometric Mean12,291,205
Coefficient Of Variation71.20
Mean Deviation23,276,287
Median42,949,000
Standard Deviation28,302,163
Sample Variance801T
Range85.2M
R-Value0.53
Mean Square Error617.4T
R-Squared0.28
Significance0.03
Slope3,148,956
Total Sum of Squares12015.2T

Cidara End Period Cash Flow History

202554 M
202441.1 M
202335.8 M
202232.7 M
202162.3 M
202042.9 M
201960.3 M

About Cidara Therapeutics Financial Statements

Cidara Therapeutics investors use historical fundamental indicators, such as Cidara Therapeutics' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cidara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow41.1 M54 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cidara Stock Analysis

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.